Canopy Growth (WEED) Stock Price, News & Analysis

Company Overview

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada to investigate the efficacy of cannabinoids for the treatment of post-concussion neurological diseases in former NHL players; and partnership with Parent Action on Drugs. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Key Stats

• Today's Range: C$1.28 to C$1.34
• 50-Day Range: C$1.27 to C$1.54
• 52-Week Range: C$1.18 to C$3.28
• Volume: 851,537 shs
• Average Volume: 1.84 million shs
• Market Capitalization: C$557.24 million
• P/E Ratio: N/A
• Dividend Yield: 4.80%
• Price Target: C$1.88
• Consensus Rating: Moderate Buy

Canopy Growth Stock Analysis - MarketRank™

Canopy Growth scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Canopy Growth has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Canopy Growth has a consensus price target of C$1.88, representing about 42.0% upside from its current price of C$1.32.

Amount of Analyst Coverage

Canopy Growth has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Canopy Growth is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Canopy Growth is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Due to a projected decrease in earnings for Canopy Growth, their PEG ratio cannot be calculated.

Price to Book Value per Share Ratio

Canopy Growth has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for WEED.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Canopy Growth is a leading dividend payer. It pays a dividend yield of 4.80%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Canopy Growth does not have a long track record of dividend growth.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: N/A

News Sentiment

Canopy Growth has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Canopy Growth insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.21% of the stock of Canopy Growth is held by insiders.

Percentage Held by Institutions

4.28% of the stock of Canopy Growth is held by institutions.

Company Calendar

• Last Earnings: 6/15/2026
• Today: 7/28/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Cannabis
• Current Symbol: TSE:WEED
• CIK: N/A
• Web: www.canopygrowth.com
• Phone: +1-613-5999600
• Fax: N/A
• Employees: 2,700
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Canopy Growth: C$1.88
• High Price Target: C$2.50
• Low Price Target: C$1.40
• Potential Upside/Downside: +42.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): C($0.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: -0.01
• Net Income: -C$1.05 billion
• Net Margins: -84.76%
• Pretax Margin: N/A
• Return on Equity: -35.48%
• Return on Assets: -3.83%

Debt

• Debt-to-Equity Ratio: 39.95
• Current Ratio: 3.34
• Quick Ratio: 2.32

Sales & Book Value

• Annual Sales: C$284.60 million
• Price / Sales: 1.96
• Cash Flow: C$0.81 per share
• Price / Cash Flow: 1.63
• Book Value: C$2.02 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 422,155,000
• Free Float: N/A
• Market Cap: C$557.24 million
• Optionable: Not Optionable
• Beta: 1.45